Shanghai Junshi Biosciences Co Ret. em ativos
Qual é o Ret. em ativos de Shanghai Junshi Biosciences Co?
O Ret. em ativos de Shanghai Junshi Biosciences Co., Ltd. é -18.56%
Qual é a definição de Ret. em ativos?
Retorno sobre os ativos indica como os ativos de uma empresa são lucrativos na geração de receita. É calculado dividindo-se o lucro líquido pelo total de ativos médios.
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. em ativos de empresas na Setor Health Care em OTC em comparação com Shanghai Junshi Biosciences Co
O que Shanghai Junshi Biosciences Co faz?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Empresas com ret. em ativos semelhantes a Shanghai Junshi Biosciences Co
- Universe Printshop tem Ret. em ativos de -18.59%
- Novacyt S.A tem Ret. em ativos de -18.59%
- Novacyt S.A tem Ret. em ativos de -18.59%
- Leigh Creek tem Ret. em ativos de -18.58%
- Bigblu Broadband plc tem Ret. em ativos de -18.57%
- Wayfair Inc tem Ret. em ativos de -18.56%
- Shanghai Junshi Biosciences Co tem Ret. em ativos de -18.56%
- ChemoCentryx Inc tem Ret. em ativos de -18.55%
- Western Asset High Income Opportunity Fund Inc tem Ret. em ativos de -18.55%
- Cairn Plc tem Ret. em ativos de -18.55%
- Cairn PLC tem Ret. em ativos de -18.55%
- Lifecore Biomedical Inc tem Ret. em ativos de -18.54%
- Netgear Inc tem Ret. em ativos de -18.53%